Belite Bio (ADR) (BLTE)
Develops oral investigational therapies for retinal and metabolic diseases.
$170.72
vs last close−4.63 (−2.64%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 23.63% | 9.47M ADS | |
|---|---|---|---|
| 82 holders · as of Jun 30, 2026 | |||
| Insiders | 1.42% | 567.3K ADS | |
| 5 holders · as of Sep 9, 2026 | |||
| Strategic holders | 42.65% | 17.10M ADS | |
| 1 holder · as of Jan 21, 2025 | |||
| Other | 32.30% | 12.95M ADS | |
| remainder | |||
40.09M ADS as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
13F, as of Jun 30, 2026
82 holders · 9.47M shares · 23 new positions · 51 increased · 22 reduced · 16 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3.08M | 7.68% | +19.8K | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 1.23M | 3.08% | +118.1K | Aug 14, 2026 |
| RTW Investments, LP | 715.3K | 1.78% | 0 | Aug 14, 2026 |
| Millennium Management LLC | 494.6K | 1.23% | −75.5K | Aug 14, 2026 |
| Maverick Capital Ltd | 396.3K | 0.99% | +396.3Knew | Aug 14, 2026 |
| Eventide Asset Management, LLC | 390.8K | 0.97% | +33.2K | Aug 14, 2026 |
| Deerfield Management Company, L.P. (Series C) | 357.2K | 0.89% | +53.2K | Aug 14, 2026 |
| Holocene Advisors, LP | 251.0K | 0.63% | −243.5K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Lin Bioscience International Ltd. | 53.70% | 17.10M | 13G | Jan 21, 2025 |
| Darwin Global Management, Ltd. | 8.10% | 3.03M | 13G | Feb 17, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 8, 2026 | Hao-Yuan Chuangdirector, officer: Chief Financial Officer | Sale · 5 lots | 17,962 | $196.42 | 26,038 |
| Sep 4, 2026 | Hao-Yuan Chuangdirector, officer: Chief Financial Officer | Sale · 14 lots | 49,433 | $187.64 | 44,000 |
| Sep 8, 2026 | Yu-Hsin Lindirector, officer: Chief Executive Officer | Sale · 5 lots | 26,000 | $196.56 | 70,134 |
| Sep 4, 2026 | Yu-Hsin Lindirector, officer: Chief Executive Officer | Sale · 14 lots | 74,435 | $187.71 | 96,134 |
| Aug 12, 2026 | Yu-Hsin Lindirector, officer: Chief Executive Officer | Sale · 2 lots | 365 | $180.35 | 170,569 |
| Aug 12, 2026 | Hao-Yuan Chuangdirector, officer: Chief Financial Officer | Sale · 2 lots | 367 | $180.35 | 93,433 |
| Jun 18, 2026 | Hendrik Peter Schollofficer: Chief Medical Officer | Sale · 5 lots | 10,000 | $145.24 | 15,000 |
| Jun 16, 2026 | Hendrik Peter Schollofficer: Chief Medical Officer | Sale · 8 lots | 10,000 | $140.57 | 25,000 |
| May 7, 2026 | Nathan L. Mataofficer: Chief Scientific Officer | Sale · 4 lots | 666 | $153.21 | 0 |
| May 6, 2026 | Nathan L. Mataofficer: Chief Scientific Officer | Sale · 6 lots | 1,000 | $153.84 | 666 |
House and Senate disclosures
Not reported.